{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:41:50Z","timestamp":1772822510618,"version":"3.50.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The authors present a case of a 67-year-old woman with primary biliary cirrhosis (Child-Pugh class B) who was treated with isavuconazole for invasive pulmonary and cerebral aspergillosis. Isavuconazole treatment was initiated with the standard maintenance dose of 200 mg daily. Therapeutic drug monitoring (TDM) was performed to target trough concentrations within the desired range of 1.0\u20135.13 mg\/L.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Real-time TDM and pharmacokinetic analyses were used to determine the dose adjustments. Liver transaminases (alanine aminotransferase and gamma-glutamyl transferase) were assessed to monitor hepatotoxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The trough plasma levels gradually increased over time up to 17.8 mg\/L. TDM-guided clinical pharmacological advice was helpful to initially reduce the dose, then to temporarily suspend drug administration, and finally to calculate the correct dose that allowed for long-term treatment up to day 258. No major signs and\/or symptoms of drug-related toxicity occurred, apart from a transient increase in gamma-glutamyl transferases that normalized after the drop in isavuconazole trough levels within the desired range.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TDM-guided clinical pharmacological advice was essential for the successful and safe management of isavuconazole treatment in this patient with moderate liver dysfunction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001064","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T15:45:01Z","timestamp":1675352701000},"page":"140-142","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Successful and Safe Real-Time TDM-Guided Treatment of Invasive Pulmonary and Cerebral Aspergillosis Using Low-Dose Isavuconazole in a Patient with Primary Biliary Cirrhosis: Grand Round\/A Case Study"],"prefix":"10.1097","volume":"45","author":[{"given":"Pier Giorgio","family":"Cojutti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy;"},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maddalena","family":"Giannella","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy;"},{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy;"},{"name":"Infectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy;"},{"name":"Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"issue":"suppl 1","key":"R1-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s40265-016-0652-6","article-title":"Isavuconazole: a review in invasive aspergillosis and mucormycosis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?","volume":"13","author":"Cojutti","year":"2021","journal-title":"Pharmaceutics"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e02474","DOI":"10.1128\/AAC.02474-18","article-title":"Isavuconazole diffusion in infected human brain","volume":"63","author":"Rouzaud","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"e01292","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.02942-15","article-title":"Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment","volume":"60","author":"Desai","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"e0178421","DOI":"10.1128\/spectrum.01784-21","article-title":"Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT Study)","volume":"10","author":"Monforte","year":"2022","journal-title":"Microbiol Spectr."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/jac\/dkz188","article-title":"Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy","volume":"74","author":"Furfaro","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:17:52Z","timestamp":1748971072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001064","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,2]]},"assertion":[{"value":"2022-09-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}